PHAT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHAT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Phathom Pharmaceuticals's other current assets for the quarter that ended in Mar. 2025 was $13.06 Mil.
Phathom Pharmaceuticals's quarterly other current assets increased from Sep. 2024 ($14.98 Mil) to Dec. 2024 ($20.87 Mil) but then declined from Dec. 2024 ($20.87 Mil) to Mar. 2025 ($13.06Mil).
Phathom Pharmaceuticals's annual other current assets increased from Dec. 2022 ($5.13 Mil) to Dec. 2023 ($13.19 Mil) increased from Dec. 2023 ($13.19 Mil) to Dec. 2024 ($20.87 Mil).
The historical data trend for Phathom Pharmaceuticals's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phathom Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Other Current Assets | Get a 7-Day Free Trial | 3.87 | 3.27 | 5.13 | 13.19 | 20.87 |
Phathom Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Other Current Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
12.75 | 15.50 | 14.98 | 20.87 | 13.06 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
James N Topper | director, 10 percent owner | 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301 |
Asit Parikh | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Molly Henderson | officer: CFO and CBO | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Azmi Nabulsi | officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
David A Socks | director, officer: President, CEO, Treas. & Sec. | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Anthony J. Guzzo | officer: VP, Chief Accounting Officer | C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Mark Stenhouse | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael F Cola | director | 435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945 |
Frazier Life Sciences Ix, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Jonathan S. Edwards | director | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
From GuruFocus
By GuruFocus News • 05-02-2025
By GuruFocus News • 05-02-2025
By Marketwired • 04-28-2025
By GuruFocus News • 05-02-2025
By Marketwired • 05-15-2025
By GuruFocus News • 05-02-2025
By GuruFocus News • 05-01-2025
By Marketwired • 05-01-2025
By GuruFocus News • 05-02-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.